NVAX Q4 2020 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$280M+3072.2% YoY

Gross Profit

$280M100.0% margin

Operating Income

-$183M-65.4% margin

Net Income

-$178M-63.5% margin

EPS (Diluted)

$-2.70

QoQ Revenue Growth

+78.1%

Cash Flow

Operating Cash Flow

-$129M

Free Cash Flow

-$171M

Stock-Based Comp.

$50M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$955M

Stockholders' Equity

$627M

Cash & Equivalents

$553M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$280M	$9M	+3072.2%
Gross Profit	$280M	$9M	+3072.2%
Operating Income	-$183M	-$29M	-537.0%
Net Income	-$178M	-$32M	-457.9%

Revenue Segments

Government Contract

$174M62%

Grant

$105M38%